Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402817 · ClinicalTrials.gov registry record · Phase 2
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01402817 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 19 participants.
The verdict
NCT01402817, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a pilot study to determine if adults and children with neurofibromatosis type 1 who have plexiform tumors given Sutent® respond to this drug therapy.
Interventions
- DRUG Sutent®/Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-03 |
| Est. Completion | 2018-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01402817
The ClinicalTrials.gov registry entry for NCT01402817 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sutent®/Sunitinib is the first listed.
NCT01402817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01402817 about?
NCT01402817 is a clinical study titled "Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas". This is a pilot study to determine if adults and children with neurofibromatosis type 1 who have plexiform tumors given Sutent® respond to this drug therapy.
What is the current status of trial NCT01402817?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-03. Estimated completion is 2018-02-14.
What interventions are being tested in trial NCT01402817?
The interventions under investigation include: Sutent®/Sunitinib (DRUG).
Who is sponsoring clinical trial NCT01402817?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.